|
|
5 April 2017 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that it was notified on 4 April 2017 that on the same day, Chris Meredith, who is a Director and PDMR, had transferred 5,900 Ordinary Shares of 5p held in the name of Platform Securities Nominees Limited (“Nominee”) to a self-invested personal pension (“SIPP”) held in his name.
The Company was also informed at the same time, that on 4 April 2017 Chris Meredith had transferred 4,780 Ordinary Shares of 5p held in the name of the Nominee to an Individual Savings Account (“ISA”) held in the name of Ingrid Meredith, the wife of Chris Meredith. The number of shares held by Chris Meredith and the beneficial ownership of the shares remains unchanged. Both transactions are part of normalised tax planning. The transfers are summarised below:
|
Director |
Number of Ordinary Shares sold from Nominee |
Price per Ordinary Share sold |
Number of Ordinary Shares purchased by SIPP |
Price paid per Ordinary Share by SIPP |
Number of Ordinary Shares purchased by ISA |
Price paid per Ordinary Share by ISA |
|
Chris Meredith |
5,900 |
249.25p |
5,900 |
249.50p |
– |
– |
|
Chris Meredith |
4,780 |
249.25p |
– |
– |
4,780 |
249.50p |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Transfer of 5,900 Ordinary Shares of 5p held in the name the Nominee to a SIPP held in the name of Chris Meredith |
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 5,900 Aggregated price: 249.25p |
||||||
|
e) |
Date of the transaction: 04/04/2017 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Transfer of 4,780 Ordinary Shares of 5p held in the name the Nominee to an ISA held in the name of Ingrid Meredith |
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 4,780 Aggregated price: 249.25p |
||||||
|
e) |
Date of the transaction: 04/04/2017 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
– End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 600 employees. For more information, please see www.admedsol.com.
This information is provided by RNS
END
DSHBDGDSDDGBGRL